{"id":"metvix-and-natural-daylight-pdt","safety":{"commonSideEffects":[{"rate":null,"effect":"Phototoxic reaction (erythema, edema)"},{"rate":null,"effect":"Burning or stinging sensation"},{"rate":null,"effect":"Crusting or scaling"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metvix is a prodrug that penetrates into dysplastic and malignant skin cells where it is converted to protoporphyrin IX, a photosensitizer. When exposed to natural daylight (rather than artificial light sources), the accumulated protoporphyrin IX is activated to produce singlet oxygen and free radicals that cause selective destruction of the abnormal tissue. This daylight-mediated photodynamic therapy (PDT) approach offers improved tolerability and convenience compared to traditional PDT with artificial lamps.","oneSentence":"Metvix (methyl aminolevulinate) is a photosensitizing agent that accumulates in abnormal skin cells and is activated by natural daylight to generate reactive oxygen species that destroy lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:59.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment with daylight PDT)"},{"name":"Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)"}]},"trialDetails":[{"nctId":"NCT02373371","phase":"PHASE3","title":"Actinic Keratoses Treatment With Metvix® in Combination With Light","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2015-03-25","conditions":"Actinic Keratoses","enrollment":26},{"nctId":"NCT01821391","phase":"PHASE3","title":"Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Actinic Keratoses","enrollment":131},{"nctId":"NCT01475071","phase":"PHASE3","title":"Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-03","conditions":"Actinic Keratoses","enrollment":100},{"nctId":"NCT02464709","phase":"PHASE4","title":"Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)","status":"COMPLETED","sponsor":"Joint Authority for Päijät-Häme Social and Health Care","startDate":"2015-06","conditions":"Actinic Keratosis, Natural Daylight Photodynamic Therapy","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metvix and natural daylight PDT","genericName":"Metvix and natural daylight PDT","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metvix (methyl aminolevulinate) is a photosensitizing agent that accumulates in abnormal skin cells and is activated by natural daylight to generate reactive oxygen species that destroy lesions. Used for Actinic keratosis (field treatment with daylight PDT), Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}